Unlabelled: Long-term persistence with anti-osteoporosis drugs and determinants for discontinuation among fracture patients were examined. Persistence was 75.0 and 45.3 % after 1 and 5 years, respectively. Those aged ≥80 years were at increased risk of early discontinuation. Within 1 year after discontinuation, 24.3 % restarted therapy, yet 47.0 % persisted for 1 year.
Introduction: The risk of osteoporotic fracture can effectively be reduced with use of anti-osteoporosis drugs. However, little is known about persistence with these drugs after fracture where subsequent fracture risk is high. The aims were to determine long-term persistence with anti-osteoporosis drugs among fracture patients, including its determinants, and to describe restart and subsequent persistence.
Methods: A cohort study was conducted within the Dutch PHARMO Database Network. Patients aged ≥50 years (n = 961) who received anti-osteoporosis drugs within 1 year after fracture, but not in the preceding year, were included (2002-2011). Persistence (defined as the proportion on treatment) and the proportion restarting after discontinuation were estimated using Kaplan-Meier analyses. Time-dependent Cox regression was used to identify determinants of non-persistence including age, sex, initial dosage regime, fracture type, comorbidities, and drug use.
Results: Persistence with anti-osteoporosis drugs was 75.0 % (95 % confidence interval (CI) 72.0-77.7) and 45.3 % (95 % CI 40.4-50.0) after 1 and 5 years, respectively. A significant determinant of non-persistence was age ≥80 years (reference 50-59 years: adjusted hazard ratio [adj. HR] 1.65; 95 % CI 1.15-2.38). This effect was not constant over time (≤360 days following initiation: adj. HR 2.07; 95 % CI 1.27-3.37; >360 days: adj. HR 1.08; 95 % CI 0.62-1.88). Within 1 year after discontinuation, 24.3 % (95 % CI 20.1-29.2) restarted therapy, yet 47.0 % persisted for 1 year.
Conclusions: This study identified suboptimal persistence with anti-osteoporosis drugs among fracture patients. Major target groups for measures aimed to improve persistence may be those aged >80 years and those restarting therapy.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4469296 | PMC |
| http://dx.doi.org/10.1007/s00198-015-3084-3 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Screening of orthopedic medicines identifies raloxifene hydrochloride as a novel ferroptosis inhibitor for spinal cord injury therapy.
Int Immunopharmacol
December 2024
Department of Orthopaedics, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang Province, China; Zhejiang Provincial Key Laboratory of Orthopaedics, Wenzhou, Zhejiang Province, China; The Second School of Medicine, Wenzhou Medical University, Wenzhou, Zhejiang Province, China. Electronic address:
Spinal cord injury (SCI) is a severe condition that can lead to irreversible central nervous system damage. Spinal cord injury patients frequently present with coexisting orthopedic conditions, and many of them also have underlying bone and joint diseases. Recent studies have identified ferroptosis as a significant contributor that exacerbates the progression of spinal cord injury.
View Article and Find Full Text PDFEvaluating the Anti-Osteoporotic Potential of Mediterranean Medicinal Plants: A Review of Current Evidence.
Pharmaceuticals (Basel)
October 2024
Department of Pharmacology, Faculty of Medicine, Universiti Kebangsaan Malaysia, Jalan Yaacob Latif, Bandar Tun Razak, Cheras, Kuala Lumpur 56000, Malaysia.
Article Synopsis
- - Bones act as reservoirs for essential minerals and cells while protecting organs and shaping the body, but osteoporosis poses a significant threat to overall quality of life.
- - There is increasing interest in using natural products and Mediterranean medicinal plants as alternatives for treating osteoporosis and preventing related fractures, though their use remains limited.
- - This article highlights seven specific Mediterranean plants and their active compounds (e.g., xanthotoxin, polyphenols) that show promise as anti-osteoporosis agents, suggesting a need for more research in developing plant-based therapies.
Advances in the study of metal-organic frameworks and their biomolecule composites for osteoporosis therapeutic applications.
Biomater Sci
November 2024
Dongguan Key Laboratory of Drug Design and Formulation Technology, Guangdong Provincial Key Laboratory of Research and Development of Natural Drugs, and School of Pharmacy, Guangdong Medical University, Guangdong Medical University Key Laboratory of Research and Development of New Medical Materials, Dongguan, 523808, China.
Article Synopsis
- The aging population is leading to an increase in osteoporosis cases, impacting patients' quality of life, and sparking interest in improving prevention and treatment methods.
- Conventional treatments mainly involve oral medications, which have limitations like side effects and potential resistance to infections, highlighting the need for alternative approaches.
- Metal-organic frameworks (MOFs) are being explored for their ability to enhance treatment outcomes for osteoporosis by controlling drug release and supporting healing, prompting a review of their therapeutic applications and future potential.
Improved solubility and bioavailability of cyclolinopeptides by diacylglycerol in the β-cyclodextrin Pickering emulsions.
Food Chem
February 2025
JNU-UPM International Joint Laboratory on Plant Oil Processing and Safety, Department of Food Science and Engineering, Jinan University, Guangzhou 510632, China. Electronic address:
Article Synopsis
- Cyclolinopeptides (CLs) have beneficial properties like anti-inflammatory and anti-tumor effects, but their low solubility limits their use.
- β-Cyclodextrin (β-CD) emulsions with camellia oil diacylglycerol (CO DAG) enhance the solubility and bioavailability of CLs significantly.
- The results show that these emulsions not only improve digestibility but also provide higher cellular absorption and anti-inflammatory effects, suggesting their potential use in functional foods and pharmaceuticals.
Ethnobotanical usages, phytochemistry, pharmacology, and quality control of chuanxiong rhizoma: A review.
J Ethnopharmacol
January 2025
Shaanxi Key Laboratory of Chinese Medicine Fundamentals and New Drugs Research, School of Pharmacy, Shaanxi University of Chinese Medicine, Xi'an, 712046, Shaanxi, PR China. Electronic address:
Article Synopsis
- Chuanxiong Rhizoma (CX), derived from the Ligusticum chuanxiong plant, is recognized in traditional Chinese medicine for its healing properties related to blood circulation and pain relief, and has a history documented in the Chinese Pharmacopoeia from 1963 to 2020.
- This study aims to thoroughly review CX's botany, traditional applications, chemical compounds, pharmacological effects, toxicity, quality control, and its absorption and metabolism in the body.
- CX has over 400 identified compounds and is used in treating various health issues, especially those affecting the cardiovascular, liver, kidney, and nervous systems, exhibiting numerous pharmacological benefits like anti-inflammatory and antioxidant effects.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!